Bajaj Finserv Healthcare Fund
The Scheme seeks to generate long term capital appreciation by predominantly investing in equity and equity related securities of pharma, healthcare and allied companies.
Growthvine rating: 1/5 — ranked #78 of 85 in category.
Fund basics
| Category | Equity: Sectoral |
|---|
| NAV | ₹11.39 (as of 2026-10-01) |
|---|
| AUM | ₹406 Cr |
|---|
| Expense ratio | 2.09% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Siddharth Chaudhary |
|---|
| Exit load | 1% for redemption within 3 months |
|---|
Performance & risk
| Standard deviation | 0.00% |
|---|
| Max drawdown | −15.91% |
|---|
| Alpha | 0 |
|---|
| Beta | 0 |
|---|
Over 5 years, captured 102.1% of NIFTY Pharma's upside and 104.3% of its downside.
Market cap allocation
| Large cap | 32.5% |
|---|
| Mid cap | 26.6% |
|---|
| Small cap | 40.9% |
|---|
Concentration
| Top 5 holdings | 38.5% |
|---|
| Top 10 holdings | 60.8% |
|---|
| Total holdings | 34 |
|---|
Top holdings
- Divis Laboratories Ltd. — 10.6%
- Sun Pharmaceutical Industries Ltd. — 8.2%
- RUBICON RESEARCH LIMITED — 6.8%
- PIRAMAL PHARMA LIMITED — 6.7%
- Aurobindo Pharma Ltd. — 6.2%
- Apollo Hospitals Enterprises Ltd. — 6.0%
- Torrent Pharmaceuticals Ltd. — 5.0%
- Neuland Laboratories Limited. — 4.1%
- Emcure Pharmaceuticals Limited — 3.8%
- Max Healthcare Institute Limited — 3.3%
Top sectors
- Pharma & Biotech — 71.3%
- Healthcare — 17.0%
- Cash — 2.7%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 18.2% | Q1 (Top) | #7 of 76 |
| 2025 | −4.6% | Q4 (Bottom) | #55 of 69 |